As of November 7, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Damora Therapeutics Inc. The largest reported stake is Fairmount Funds Management LLC's, at 19.99%. 18 filings are on record since September 25, 2025 (Schedule 13D/A, February 11, 2026).
Sell to companies like Damora Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 3,072,238 · Shared voting: 0 · Sole dispositive: 3,143,576 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-28
- · Holder: Avoro Capital Advisors LLC · Percent: 6.27% · SCHEDULE 13G
- · Holder: Jain Global LLC · Percent: 0% · SCHEDULE 13G/A
- · Holder: Point72 Asset Management, L.P. · Percent: 2% · SCHEDULE 13G/A
- · Holder: Paragon Therapeutics, Inc. · Percent: 3.39% · SCHEDULE 13G/A
Damora Therapeutics Inc has 18 Schedule 13D or 13G filings on record since 2025-09-25. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fairmount Funds Management LLC | 19.99% | 8,713,000 | SCHEDULE 13D/A, 2026-02-11 | 2026-02-09 |
| Fmr LLC | 15% | 238,878 | SCHEDULE 13G, 2025-12-05 | 2025-11-28 |
| Avoro Capital Advisors LLC | 6.27% | 3,783,000 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Venrock Healthcare Capital Partners III, L.P. | 6% | 3,603,595 | SCHEDULE 13G, 2026-02-17 | 2026-02-09 |
| BlackRock, Inc. | 5.1% | 3,143,576 | SCHEDULE 13G, 2026-07-28 | 2026-06-30 |
| Paragon Therapeutics, Inc. | 3.39% | 2,045,473 | SCHEDULE 13G/A, 2026-04-23 | 2026-02-09 |
| Paramora Holding LLC | 3.39% | 2,045,473 | SCHEDULE 13G/A, 2026-04-23 | 2026-02-09 |
| Point72 Asset Management, L.P. | 2% | 1,193,708 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Ikarian Capital, LLC | 0.6% | 335,710 | SCHEDULE 13G/A, 2026-03-06 | 2026-02-28 |
| Novo Holdings A/S | 0% | 0 | SCHEDULE 13D/A, 2025-10-09 | 2025-10-07 |
| Jain Global LLC | 0% | 0 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind Damora Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Damora Therapeutics Inc and the records around it.
Damora Therapeutics Inc elsewhere on the record
- Leadership changes May 2026
- Form D filing Nov 2025
- Who owns it
Companies that share a holder
- Jain Global LLC also filed stake reports on 3 other companies: M3-Brigade Acquisition V Corp. (Mar 2026), 1RT Acquisition Corp. (Nov 2025), INFINITY NATURAL RESOURCES, INC. (Aug 2025)
- Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026)
- Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
Watch Damora Therapeutics Inc
Get an email when Damora Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Damora Therapeutics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Damora Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Damora Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3,072,238 | 0 | 3,143,576 | 0 | SCHEDULE 13G, 2026-07-28 |
The latest filing identifies Damora Therapeutics Inc by CUSIP 36322Q206 and gives its principal executive office as 221 Crescent Street, Building 23, Suite, Waltham, MA 02453 (SCHEDULE 13G, 2026-07-28).
Purpose of Transaction (Item 4)
Fairmount Funds Management LLC
Item 4 of the Statement is hereby amended and supplemented as follows: Conversion of Series C Preferred Stock Pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of the Series C Non-Voting Convertible Preferred Stock, dated November 7, 2025 (as corrected, the "Certificate of Designation"), following stockholder approval received on February 9, 2026 of the issuance of shares of Common Stock upon conversion of the Series C Preferred Stock, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to beneficial ownership limitations (the "Conversion"). On February 9, 2026, 5,809 shares of Series C Preferred Stock held by Fund II and 2,904 shares of Series C Preferred Stock held by Co-Invest automatically converted into 5,809,000 shares of Common Stock and 2,904,000 shares of Common Stock, respectively. Lock-up Agreements The securities of the Issuer held by the Reporting Persons, including the shares of Common Stock received upon conversion of the Series C Preferred Stock, are subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's public offering, pursuant to which certain of the Reporting Persons agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 60 days following the date of the final prospectus supplement relating to the public offering, which was February 10, …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-02-11; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-25 | Novo Holdings A/S | 6.5% | SCHEDULE 13D/A |
| 2025-10-09 | Novo Holdings A/S | 0% | SCHEDULE 13D/A |
| 2025-11-13 | Point72 Asset Management, L.P. | 6.3% | SCHEDULE 13G |
| 2025-11-17 | Fairmount Funds Management LLC | 19.99% | SCHEDULE 13D |
| 2025-12-05 | Fmr LLC | 15% | SCHEDULE 13G |
| 2025-12-05 | Ikarian Capital, LLC | 21.5% | SCHEDULE 13G |
| 2026-01-12 | Paragon Therapeutics, Inc. | 7.5% | SCHEDULE 13G |
| 2026-01-12 | Paramora Holding LLC | 7.5% | SCHEDULE 13G |
| 2026-02-11 | Fairmount Funds Management LLC | 19.99% | SCHEDULE 13D/A |
| 2026-02-17 | Jain Global LLC | 7.5% | SCHEDULE 13G |
| 2026-02-17 | Venrock Healthcare Capital Partners III, L.P. | 6% | SCHEDULE 13G |
| 2026-03-06 | Ikarian Capital, LLC | 0.6% | SCHEDULE 13G/A |
| 2026-04-23 | Paragon Therapeutics, Inc. | 3.39% | SCHEDULE 13G/A |
| 2026-04-23 | Paramora Holding LLC | 3.39% | SCHEDULE 13G/A |
| 2026-05-15 | Avoro Capital Advisors LLC | 6.27% | SCHEDULE 13G |
| 2026-05-15 | Jain Global LLC | 0% | SCHEDULE 13G/A |
| 2026-05-15 | Point72 Asset Management, L.P. | 2% | SCHEDULE 13G/A |
| 2026-07-28 | BlackRock, Inc. | 5.1% | SCHEDULE 13G |
Questions about who owns Damora Therapeutics Inc
Who owns Damora Therapeutics Inc?
On this page, 5 holders' latest ownership filings report 5% or more of Damora Therapeutics Inc: Fairmount Funds Management LLC (19.99%, Schedule 13D/A, filed 2026-02-11), Fmr LLC (15%, Schedule 13G, filed 2025-12-05), Avoro Capital Advisors LLC (6.27%, Schedule 13G, filed 2026-05-15), Venrock Healthcare Capital Partners III, L.P. (6%, Schedule 13G, filed 2026-02-17) and BlackRock, Inc. (5.1%, Schedule 13G, filed 2026-07-28).
Who are the largest shareholders of Damora Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Damora Therapeutics Inc on this page are Fairmount Funds Management LLC (19.99%), Fmr LLC (15%) and Avoro Capital Advisors LLC (6.27%).
When did Fairmount Funds Management LLC buy into Damora Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Fairmount Funds Management LLC on this page is the Schedule 13D, filed 2025-11-17, reporting 19.99%; its latest, Schedule 13D/A filed 2026-02-11, reports 19.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 18 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Damora Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 4, 2026 | Leadership change: Brian Burkavage appointed, Senior Vice President, Finance | — | Leadership changes | Source |
| November 21, 2025 | Form D, private offering | $285M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Damora Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.